Rebuilding the damaged heart: the potential of cytokines and growth factors in the treatment of ischemic heart disease.
Cytokine therapy promises to provide a noninvasive treatment option for ischemic heart disease. Cytokines are thought to influence angiogenesis directly via effects on endothelial cells or indirectly through progenitor cell-based mechanisms or by activating the expression of other angiogenic agents. Several cytokines mobilize progenitor cells from the bone marrow or are involved in the homing of mobilized cells to ischemic tissue. The recruited cells contribute to myocardial regeneration both as a structural component of the regenerating tissue and by secreting angiogenic or antiapoptotic factors, including cytokines. To date, randomized, controlled clinical trials have not reproduced the efficacy observed in pre-clinical and small-scale clinical investigations. Nevertheless, the list of promising cytokines continues to grow, and combinations of cytokines, with or without concurrent progenitor cell therapy, warrant further investigation.
Beohar
Nirat
N
Northwestern University, Chicago, IL, USA.
Rapp
Jonathan
J
Pandya
Sanjay
S
Losordo
Douglas W
DW
D003331:Coronary Vessels / Q000187:drug effects*; D016207:Cytokines / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000494:pharmacology / Q000627:therapeutic use; D017202:Myocardial Ischemia / Q000188:drug therapy*; D018919:Neovascularization, Physiologic; D016896:Treatment Outcome
D016207:Cytokines; D036341:Intercellular Signaling Peptides and Proteins